Anakinra for lingering symptoms after COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have confirmed COVID-19 infection at least 90 days ago
- Still have post-acute COVID symptoms for more than 2 months that limit daily life
- Have blood test evidence of inflammation (IP-10 above 250 pg/mL)
- Meet lung-related findings (abnormal lung tests and/or CT scan score over 20, or a 6-minute walk distance under 500 meters)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called Anktiva to see if it can help people with Long COVID. It's for adults who had a confirmed COVID-19 infection and now have lasting symptoms like fatigue, brain fog, or trouble breathing.
This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.
This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.
This study tests if the drug Anktiva can help people with long COVID. To join, you must have had at least one confirmed COVID-19 infection and now have lasting symptoms that started or got worse after that infection.
This trial tests a treatment made from donated umbilical cord blood, called REGENECYTE, to see if it helps people with long COVID feel better. It is for adults who still have symptoms after COVID-19 and have tested negative for the virus recently.
This trial tests if aripiprazole, a medication often used for other conditions, can help improve neuropsychiatric symptoms like brain fog, mood changes, or fatigue that started after an infection and have lasted at least 3 months.
Hear when a new Post-Acute COVID-19 Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.